• Explore /
  • Poster
  • / Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.

Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.

Abstract Poster

Authors

Taofeek Owonikoko

Taofeek Kunle Owonikoko

Emory University, Atlanta, GA

Taofeek Kunle Owonikoko , Kyriakos P. Papadopoulos , Melissa Lynne Johnson , Marta Gil Martin , Victor Moreno , April K.S. Salama , Emiliano Calvo , Nelson S Yee , Howard Safran , Antonio González-Martín , Raid Aljumaily , Daruka Mahadevan , Jiaxin Niu , Kosalai Kal Mohan , Jingjin Li , Elizabeth Stankevich , Israel Lowy , Matthew G. Fury , Hani M. Babiker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02383212

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9557)

DOI

10.1200/JCO.2018.36.15_suppl.9557

Abstract #

9557

Poster Bd #

384

Abstract Disclosures

Similar Posters

First Author: Kyriakos P Papadopoulos

First Author: Xue Bai

First Author: Gang Jin

First Author: Jianming Xu